AL-ADTRAN
21.3.2024 14:01:36 CET | Business Wire | Press release
Adtran today launched its FSP 3000 M-Flex800™, enabling network operators to unlock the full potential of ZR and ZR+ optics for high-capacity transport solutions across edge, metro and core networks. This single-slot card – the newest addition to Adtran’s coherent optical technology suite – offers a universal host for ZR and ZR+ optics and addresses many of the shortfalls of IP-over-DWDM (IPoWDM) solutions. Compared to classical OTN muxponder solutions, M-Flex800™ supports much simpler demarcation and multiplexing technology. Combined with the use of a wide range of ZR optics, this enables a new way to develop compact and low-power transport solutions from the edge to the core. This new IP-to-DWDM approach enables flexible, cost-efficient networking with separated IP and optical layers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321282596/en/
Adtran’s FSP 3000 M-Flex800™ is a one-slot card that acts as a universal host for ZR, ZR+ and OpenROADM coherent interfaces. (Photo: Business Wire)
“Initially developed for DCI, ZR optics are now expanding their reach into diverse operational environments. Today’s launch will be key in that transition. Our new FSP 3000 M-Flex800™ will be a gateway between classical DWDM and the latest IPoDWDM, bringing the benefits of standardized ZR optics to a broad spectrum of operators,” said Christoph Glingener, CTO of Adtran. “Our versatile one-slot card acts as a universal host for ZR, ZR+ and OpenROADM coherent interfaces, seamlessly integrating into any open line system and enabling multiple use cases. Whether you’re looking to deploy in carrier infrastructure or DCI environments, in central offices or street cabinets, our M-Flex800™ can be easily slotted into any FSP 3000 chassis.”
The Adtran FSP 3000 M-Flex800™ is a versatile, multi-rate line card able to support an extensive range of grey and coherent interfaces, including 100Gbit/s, 400Gbit/s, 800Gbit/s, ZR, ZR+, OpenROADM and other types of coherent optics. Designed to meet the high-capacity connectivity needs of telecom operators, cloud providers and enterprises, it facilitates a range of applications from the edge to the core. This universal host simplifies upgrades to 800Gbit/s line speeds and Ethernet services and can multiplex 100GbE, 400GbE and OTU4 services into line speeds up to 800Gbit/s. Suited for tasks such as IP and optical demarcation, ZR-to-ZR interconnects and edge OTN applications, the Adtran FSP 3000 M-Flex800™ offers a cost-effective and low-power solution in a single-slot card.
“With its exceptional flexibility, operational simplicity and compact footprint, our FSP 3000 M-Flex800™ caters to diverse environments, from data centers to space-restricted street cabinets. Its ability to reduce power consumption while supporting high-capacity, open and scalable transport is a testament to our commitment to driving the next generation of transport infrastructure,” commented Ryan Schmidt, GM of optical transport at Adtran. “We’re addressing the core needs of network operators across a broad spectrum of applications, even beyond the traditional transponder/muxponder use cases. Today’s launch marks a big step towards more efficient, versatile and cost-effective infrastructure.”
Further information on the FSP 3000 M-Flex800™ is available in these slides.
A supporting product video is also available to watch.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321282596/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 12:17:00 CEST | Press release
Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 11:11:00 CEST | Press release
- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechno
The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 09:00:00 CEST | Press release
New One-Day Intensive Experience Offered 9 June Ahead of Conference 10-11 June at Tobacco Dock Featuring 10 Stages and 14 Tracks The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom